What Thymosin alpha-1 is
Thymosin alpha-1 is an immune-modulating peptide studied in infectious disease, oncology-adjacent, and immune response contexts.
Thymosin alpha-1 is grouped under Longevity + Skin / Approved / Clinical on PeptideFactCheck because it is popular with longevity and immune optimization audiences but has a more clinical research footprint than many internet peptides.
The useful starting point is to separate the molecule itself from the internet story around it. It is popular because it sounds like an immune-system calibration peptide.
Why people keep looking it up
People discuss thymosin alpha-1 for immune support and resilience.
Thymosin alpha-1 is studied around immune signaling and T-cell context.
Thymosin alpha-1 tends to stay in the conversation because it touches a familiar public theme: immune modulation, t-cell signaling, and thymic peptide. That makes it easy for the claim to travel faster than the evidence.
What the evidence can support right now
There is human clinical literature, but general wellness immune claims need careful boundaries.
Human studies exist in specific clinical contexts. Claims about general immune optimization need careful separation.
Mechanistic work focuses on immune signaling, T-cell context, and host-defense pathways.
Why this page carries the current tier: Human clinical literature exists, but regulatory and claim scope are indication-specific.
The current seed trail for Thymosin alpha-1 is pulling from 1 literature source, 1 trials source, and 1 databases source.
Safety, limits, and regulatory context
Disease-context findings should not be converted into generalized wellness claims without evidence.
Approval status varies internationally. This V1 profile does not list a U.S. FDA-approved thymosin alpha-1 product.
Editorial boundary: PeptideFactCheck does not publish dosing, cycling, sourcing, injection, or administration instructions for Thymosin alpha-1. The job here is to explain the public claim, the mechanism story, the evidence strength, and the current limits.
Molecular and identifier data
The current PubChem match for Thymosin alpha-1 is CID 16130571. That gives the page a source-backed chemistry record rather than a placeholder identifier block.
- PubChem CID
- 16130571
- Formula
- C129H215N33O55
- Molecular weight
- 3108.3
- InChIKey
- NZVYCXVTEHPMHE-ZSUJOUNUSA-N
Matched synonyms include Thymalfasin, 62304-98-7, Thymosin alpha 1, Thymosin alpha1, Zadaxin, alpha1-Thymosin, Thymosin alpha1 (human), thymalfasine.
Open PubChem recordClinical trial snapshot
The current ClinicalTrials.gov intervention query for Thymosin alpha-1 returns 61 study records. This does not prove efficacy by itself, but it does show whether the peptide is showing up in a formal trial registry rather than only in forums or vendor copy.
Literature snapshot
The current PubMed query for Thymosin alpha-1 returns 774 results. The articles below are a quick literature surface so the page shows actual papers instead of only generic evidence labels.
Source trail
Each linked source is shown directly so the page can be audited. The page now combines its editorial seed trail with automated official-source enrichment generated on 2026-04-24 from PubChem, ClinicalTrials.gov, PubMed, DailyMed, openFDA label, and Drugs@FDA.